Hologic (NASDAQ: HOLX) director receives 3,190 stock unit award

Rhea-AI Filing Summary

McMillan Wayde D. reported acquisition or exercise transactions in this Form 4 filing.

Hologic, Inc. director Wayde D. McMillan reported receiving an equity award of 3,190 restricted stock units of common stock. The award was granted at no cash cost per share and will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders.

Each restricted stock unit will be settled in one share of Hologic common stock upon vesting. Following this grant, McMillan’s directly held common stock position increased to 4,932 shares, reflecting his equity-based alignment with shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McMillan Wayde D.

(Last) (First) (Middle)

250 CAMPUS DRIVE

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		3,190(1)	A	(2)	4,932	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.

2. Restricted stock units are settled in shares of common stock on a one-for-one basis.

	/s/ Mark W. Irving, attorney-in-fact for Mr. McMillan	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Hologic (HOLX) disclose for Wayde D. McMillan?

Hologic reported that director Wayde D. McMillan received a grant of 3,190 restricted stock units of common stock. These units were awarded at no cash price and represent additional equity compensation, increasing his directly held common share position after the grant.

How many Hologic (HOLX) shares does Wayde D. McMillan hold after this Form 4?

After the reported equity award, Wayde D. McMillan directly holds 4,932 shares of Hologic common stock. This figure reflects his updated direct ownership position following the grant of 3,190 restricted stock units reported in the Form 4 filing.

What type of securities were granted to the Hologic (HOLX) director in this filing?

The director received restricted stock units tied to Hologic common stock. Each restricted stock unit will be settled in one share of common stock, providing equity-based compensation that aligns the director’s interests with long-term shareholder value as the units vest and convert to shares.

When do Wayde D. McMillan’s Hologic (HOLX) restricted stock units vest?

The restricted stock units vest on the date of Hologic’s 2027 Annual Meeting of Stockholders. On that vesting date, the units are scheduled to be settled in shares of common stock, assuming applicable conditions are met for the award’s vesting and settlement.

What does the zero transaction price mean in the Hologic (HOLX) Form 4 award?

The zero transaction price indicates the director did not pay cash for the 3,190 restricted stock units. This reflects a grant or award of equity compensation, rather than an open-market purchase of shares, consistent with the Form 4 code for a grant or award acquisition.